EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: Post hoc analysis of three randomised controlled trials

Matthew J Armstrong, Takeshi Okanoue, Mads Sundby Palle, Anne-Sophie Sejling, Mohamed Tawfik, Michael Roden

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16065 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Matthew J Armstrong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Liver Unit, Queen Elizabeth University Hospital, Birmingham, UK. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Diabetes Mellitus, Type 2, Weight Loss, Hypoglycemic Agents. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Weight loss mediated by glucagon‐like peptide‐1 (GLP‐1) analogues is lower in patients with type 2 diabetes versus those without. Type 2 diabetes and obesity are risk factors for metabolic dysfunction‐associated steatotic liver disease (MASLD) and associated steatohepatitis (MASH). We evaluated weight changes in adults with MASLD/MASH with or without type 2 diabetes receiving the GLP‐1 analogue semaglutide. Materials and Methods This was a post hoc analysis of data from three 48–72‐week randomised trials investigating the effect of semaglutide versus placebo in adults with MASLD (NCT03357380) or biopsy‐confirmed MASH (NCT02970942 and NCT03987451). Pooled data for semaglutide (0.4 mg once daily and 2.4 mg once weekly [ n = 163]) and placebo ( n = 137) were analysed at 1 year. Weight changes were analysed by type 2 diabetes status (type 2 diabetes [ n = 209], pre‐type 2 diabetes [ n = 51] and no diabetes [ n = 40]) and by other cardiometabolic risk parameters using analysis of covariance and Spearman's rank correlations.

Results

The overall mean weight change was −11.1 kg (−11.7%) and −0.7 kg (−0.6%) with semaglutide and placebo, respectively. While numerically higher for people without type 2 diabetes, estimated treatment differences with semaglutide versus placebo were similar overall for people with type 2 diabetes (−10.2 kg; −10.8%), pre‐type 2 diabetes (−9.8 kg; −10.2%) and no diabetes (−11.6 kg; −13.1%). Differences between groups were not statistically significant ( p > 0.50 for all). Baseline fasting plasma glucose, glycated haemoglobin, insulin levels, insulin resistance and lipids did not correlate with weight change.

Conclusions

People with MASLD/MASH had similar semaglutide‐mediated weight loss regardless of type 2 diabetes status and other cardiometabolic risk parameters.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesDiabetes Mellitus, Type 2Weight LossHypoglycemic AgentsCardiometabolic Risk FactorsHumansMiddle AgedFemaleMaleFatty LiverAgedAdultNon-alcoholic Fatty Liver DiseaseObesitySemaglutide

Stichwörter der Autor:innen

GLP‐1 analoguesemaglutidetype 2 diabetesweight control

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsSemaglutide

Autor:innen und Institutionen

  • Liver Unit, Queen Elizabeth University Hospital, Birmingham, UK.
  • National Institute for Health Research, Birmingham Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Centre for Liver & Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital, Osaka, Japan.
  • Novo Nordisk A/S, Søborg, Denmark.
  • Division of Endocrinology and Diabetology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.

Förderung

  • Novo Nordisk A/S

Zitieren

APA

Armstrong, M. J., Okanoue, T., Sundby Palle, M., Sejling, A. S., Tawfik, M., & Roden, M. (2025). Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: Post hoc analysis of three randomised controlled trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16065

Vancouver

Armstrong MJ, Okanoue T, Sundby Palle M, Sejling AS, Tawfik M, Roden M. Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: Post hoc analysis of three randomised controlled trials. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16065

BibTeX
@article{Armstrong2025,
  author = {Armstrong, Matthew J and Okanoue, Takeshi and Sundby Palle, Mads and Sejling, Anne-Sophie and Tawfik, Mohamed and Roden, Michael},
  title = {Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: Post hoc analysis of three randomised controlled trials},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16065}
}
Kostenlos starten →